Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1222200 | 0.87 | SMPD1 (0.77) | ALDH1A1HPGDPTPN1SMPD1NR4A2 | |
| SCHEMBL4791629 | 0.84 | ALDH1A1 (0.73) | ALDH1A1HPGDPTPN1 | |
| SCHEMBL1179647 | 0.80 | ALDH1A1 (1.00) | ALDH1A1HPGDPTPN1 | |
| SCHEMBL4896931 | 0.78 | MRGPRX4 (0.53) | ALDH1A1MRGPRX4NR4A2P4HTMNR1H4 | |
| SCHEMBL5620215 | 0.77 | PTPN1 (1.00) | ALDH1A1HPGDPTPN1 | |
| SCHEMBL71299 | 0.77 | ALDH1A1 (1.00) | ALDH1A1HPGDPTPN1 | |
| SCHEMBL71318 | 0.76 | BRD4 (0.67) | ALDH1A1HPGDSMPD1LMNA | |
| SCHEMBL11902016 | 0.76 | ALDH1A1 (0.69) | ALDH1A1HPGDPTPN1 | |
| SCHEMBL72387 | 0.76 | PTPN1 (0.78) | ALDH1A1HPGDPTPN1 | |
| SCHEMBL68122 | 0.76 | MRGPRX4 (0.54) | PTPN1MRGPRX4NR4A2P4HTMNR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842696-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-30 | — | — | US | disclosed |
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-03 | — | — | US | disclosed |
| WO-2008157844-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221583-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | ALDH1A1 969/4885HPGD 503/4885PTPN1 4580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.